With special interest in the production of fundamental and applied research, the group is working on designing nanoparticles with applications in the field of medicine. At the same time, the research they are conducting places special emphasis on safety, viability, extension, applicability, and other aspects related to nanoparticle engineering.

The group is currently focusing on putting into practice ALK translocation, studying how effective PI3K/mTOR inhibitors are in patients with EGFR-TKI-resistant lung cancer, and studying how effective PARP inhibitors are in lung cancer.

They are analysing the epidemiological and clinical characteristics of women diagnosed with lung cancer. They are committed to reinforcing a multidisciplinary approach to provide the best care for patients, and are proactive in the fight against smoking.

Focusing on tumours in the digestive system, the group is working on diagnosis and prognosis tools in this type of condition, in order to get closer to early and more effective treatment. It is also studying the genetic and epigenetic causes and some of the mechanisms that occur in tumours, in order to increase the knowledge of the peculiarities of this type of cancer. In short, it is gaining deeper knowledge of the molecular mechanisms responsible for tumour formation, allowing diagnosis and treatment to be improved.

It is dedicated to research into viral, fungal and bacterial infections in immunosuppressed paediatric patients. It is a pioneering unit in this filed and national point of reference, with a high level of expertise. The unit’s research also reflects on daily clinical practice.

Visit the research group’s page

Among the group’s current objectives is putting into practice tumour sequencing in patients with breast cancer. We are studying the efficacy of PI3K/mTOR inhibitors and their relationship with mutational state, as well as continuing research on the factors involved in resistance to HER2 treatments and the strategies aimed at reversing them.

We are also studying how effective PARP inhibitors are in breast cancer and investigating the implementation of therapeutic strategies and differentiated clinical trials for tumour subtypes.

The group is working on developing biomarkers, with the help of bioinformatic tools, and on the prediction of pathological mutations. In this last field, they are already applying the tools and approaches developed in specific pathologies, as a natural step towards developing personalised medicine.

Visit the research group’s page

We are looking for therapeutic targets and secretory tumour biomarkers based on signal transduction systems, using quantitative proteome methods. They also characterise the influence of non-classical secretion during tumour formation, especially in tumour invasion and metastasis.

Visit the research group’s page

They are developing innovative therapeutic strategies to treat HER2 positive tumours and to identify mechanisms of resistance to current treatments. Working on the characterisation of the role of premature senescence in the progression and treatment of breast cancer, and the study of the implications of the immune system for the progression of cancer.

As well as its work on researching the molecular bases of several of these rare diseases, one aspect common to all the group’s projects is research on transferring findings in the fields of molecular diagnosis, genetic counselling and new genetic or pharmacological therapies. In order to make these discoveries, they dedicate part of their research to the molecules involved in the physiopathological mechanism of the diseased studies, always in direct relation to patient consultation.

The group has established a pioneering programme on detection of congenital heart defects and chromosome abnormalities. They are also investigating the long-term impact of an adverse environment during gestation for maternal and child health (growth restriction, preeclampsia, prematurity, breast cancer during pregnancy). Its other lines of research are dedicated to the effects that obesity or breast cancer may have on pregnancy.